Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 14 , ISSUE 1 ( January-June, 2024 ) > List of Articles

Original Article

Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi

Nazish Butt, Muhammad T Usmani, Riaz Hussain, Saba Mughal, Fakhar A Qazi Arisar

Keywords : Hepatitis delta virus, Outcomes, Pakistan, Treatment, Virological response

Citation Information : Butt N, Usmani MT, Hussain R, Mughal S, Arisar FA. Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi. Euroasian J Hepatogastroenterol 2024; 14 (1):51-55.

DOI: 10.5005/jp-journals-10018-1431

License: CC BY-NC 4.0

Published Online: 12-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Chronic hepatitis D (CHD) along with chronic hepatitis B (CHB) is an important cause of morbidity and mortality in patients with cirrhosis. It is a potentially curable infection that has long awaited a good treatment option. Objective: To ascertain the efficacy of pegylated interferon (PEG-IFN)-alpha-2a in patients suffering from CHD. A tertiary care hospital experience from Pakistan. Materials and methods: The study included 207 CHD polymerase chain reaction (PCR)-positive patients treated with PEG-IFN-alpha-2a between July 2020 and October 2022. Virological response rate (PCR negative) at weeks 24 and 48 was the primary endpoint. Secondary outcomes included partial response (>2 log reduction in PCR) and treatment failure rate (<2 log reduction in PCR). Results: A total of 187 patients started PEG-IFN therapy, and 148 patients completed the assigned 48 weeks of therapy. Patients’ mean age was 25.7 years with 65% being males. The virological response rate was 40.5% at week 24 and 32.4% at week 48. The partial response rate was 24% at both weeks 24 and 48. The treatment failure rate was 36% at week 24 and 44% at week 48. Hemoglobin, white blood cell (WBC) count, and total bilirubin were found to be predictive of treatment response. Side effects led to treatment discontinuation among eighteen patients and one patient died due to hepatic failure. Conclusion: Therapy with PEG-IFN-alpha-2a shows suboptimal outcomes in patients with CHD. There is a strong need for more effective alternate therapies for CHD patients.


PDF Share
  1. Rizzetto M, Canese MG, Aricò S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977;18(12):997–1003. DOI: 10.1136/gut.18.12.997.
  2. Abbas Z, Khan MA, Salih M, et al. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011;2011(12):CD006002. DOI: 10.1002/14651858.CD006002.pub2.
  3. Abbas Z, Qadeer MA, Mandviwalla HA, et al. The severity of hepatitis D in young adults of age 18–25 Years. Cureus 2020;12(10):e10855. DOI: 10.7759/cureus.10855.
  4. Abbas Z. Hepatitis D in Pakistan. J Coll Physicians Surg Pak 2012;22(9):547–548. PMID: 22980605.
  5. Wranke A, Borzacov LMP, Parana R, et al. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int 2018;38(5):842–850. DOI: 10.1111/liv.13604.
  6. Abbas Z, Abbas M. Management of hepatitis delta: Need for novel therapeutic options. World J Gastroenterol 2015;21(32):9461–9465. DOI: 10.3748/wjg.v21.i32.9461.
  7. Abbas Z, Memon MS, Mithani H, et al. Treatment of chronic hepatitis D patients with pegylated interferon: A real-world experience. Antivir Ther 2014;19(5):463–468. DOI: 10.3851/IMP2728.
  8. Deterding K, Wedemeyer H. Beyond pegylated interferon-alpha: New treatments for hepatitis delta. AIDS Rev 2019;21(3):126–134. DOI: 10.24875/AIDSRev.19000080.
  9. Etzion O, Hamid S, Lurie Y, et al. Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial. Hepatology 2023;77(6):2093–2103. DOI: 10.1097/HEP.0000000000000309.
  10. Alavian SM, Tabatabaei SV, Behnava B, et al. Standard and pegylated interferon therapy of HDV infection: A systematic review and meta-analysis. J Res Med Sci 2012;17(10):967–974. PMID: 23825999.
  11. Rizzetto M. Treatment of chronic delta hepatitis. Hepat Mon 2011;11(9):701–702. DOI: 10.5812/kowsar.1735143X.759.
  12. Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: In need of revision. Hepatology 2015;61(4):1109–1111. DOI: 10.1002/hep.27585.
  13. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006;44(3):713–720. DOI: 10.1002/hep.21296.
  14. Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs 1997;53(1):74–85. DOI: 10.2165/00003495-199753010-00005.
  15. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994;14(3):154–157. DOI: 10.1111/j.1600-0676.1994.tb00065.x.
  16. Da BL. Clinical trials in hepatitis D virus: Measuring success. Hepatology 2023;77(6):2147–2157. DOI: 10.1002/hep.32732.
  17. Lok AS, Negro F, Asselah T, et al. Endpoints and new options for treatment of chronic hepatitis D. Hepatology 2021;74(6):3479–3485. DOI: 10.1002/hep.32082.
  18. Alfaiate D, Clément S, Gomes D, et al. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020;73(3):533–539. DOI: 10.1016/j.jhep.2020.02.030.
  19. Mumtaz K, Hamid SS, Adil S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. J Gastroenterol Hepatol 2005;20(10):1503–1507. DOI: 10.1111/j.1440-1746.2005.03857.x.
  20. Anastasiou OE, Yurdaydin C, Maasoumy B, et al. A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. J Viral Hepat 2021;28(2):410–419. DOI: 10.1111/jvh.13439.
  21. Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis 2012;32(3):237–244. DOI: 10.1055/s-0032-1323629.
  22. Keskin O, Yurdaydin C. Letter to the editor: Interferon is not an optimal treatment for chronic hepatitis delta but needs “fair treatment” by us. Hepatology 2012;74(2):1127. DOI: 10.1002/hep.31501.
  23. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006;26(7): 805–810. DOI: 10.1111/j.1478-3231.2006.01279.x.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.